Cas:112581-74-5 2,5,7-trimethylpyrazolo[1,5-a]pyrimidine manufacturer & supplier

Chemical Name:2,5,7-trimethylpyrazolo[1,5-a]pyrimidine

CAS.NO:112581-74-5

Synonyms:2,5,7-trimethylpyrazolo<1,5-a>pyrimidine

Molecular Formula:C₉H₁₁N₃

Molecular Weight:161.20400

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.16g/cm3

Index of Refraction:1.619

PSA:30.19000

Exact Mass:161.09500

LogP:1.65450

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,5,7-trimethylpyrazolo&lt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pyrimidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,5,7-trimethylpyrazolo&lt Use and application,2,5,7-trimethylpyrazolo&lt technical grade,usp/ep/jp grade.

Related News: US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 2,5,7-trimethylpyrazolo[1,5-a]pyrimidine manufacturer Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. 2,5,7-trimethylpyrazolo[1,5-a]pyrimidine supplier A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 2,5,7-trimethylpyrazolo[1,5-a]pyrimidine vendor Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. 2,5,7-trimethylpyrazolo[1,5-a]pyrimidine factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.